Detail akcie Imunon Rg online

Business Summary: Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Imunon Inc revenues was not reported. Net loss decreased 29% to $10.3M. Lower net loss reflects Research and development - Balancing val decrease of 43% to $5.3M (expense), General and administrative - Balancing v decrease of 7% to $5M (expense), Stock-based Compensation in R&D decrease of 86% to $29K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$17.86 to -$6.55.